Trial Profile
Efficacy of minodronate and denosumab for bone loss in patients with prostate cancer undergoing androgen deprivation therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Minodronic acid (Primary) ; Alfacalcidol
- Indications Metabolic bone diseases; Osteoporosis
- Focus Therapeutic Use
- Acronyms PROMADE
- 09 Dec 2020 Status changed from active, no longer recruiting to completed.
- 09 Jul 2019 Planned number of patients changed from 150 to 99.
- 10 Mar 2018 Status changed from recruiting to active, no longer recruiting.